Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions.

European journal of cancer (Oxford, England : 1990) - 1 Oct 2020

Gebhardt Christoffer, Ascierto Paolo, Atkinson Victoria, Corrie Pippa, Dummer Reinhard, Schadendorf Dirk

Abstract excerpt

Patients with BRAF-mutant melanoma commonly develop resistance to BRAF inhibitor and MEK inhibitor (BRAF/MEKi) treatment, resulting in disease recurrence or progression. Repeated treatment after a break or an intervening therapy may provide clinical benefit. To ensure a common understanding when discussing the treatment of BRAF-mutant melanoma, we propose consensus definitions for retreatment and rechallenge....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to MAP Kinase Signaling System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Mitogen-Activated Protein Kinase Kinases

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Retreatment

Share to Skin Neoplasms

Source

Identifiers

PMID: 32861208
DOI: 10.1016/j.ejca.2020.07.016

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions.PMID 32861208Read ↗

BRAF/MEK inhibitor rechallenge in advanced melanoma patients.Semantic proximity Read ↗

Repeated complete response with long-term control of BRAF-mutant melanoma by multiple rechallenges with dabrafenib plus trametinib.Semantic proximity Read ↗

Melanoma: BRAFi Rechallenge.Semantic proximity Read ↗

Successful rechallenge therapy for BRAF/MEK inhibitor-resistant multiple brain metastases of melanoma.Semantic proximity Read ↗

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.Semantic proximity Read ↗

BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes.Semantic proximity Read ↗

Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma.Semantic proximity Read ↗

Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient.Semantic proximity Read ↗

EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.Semantic proximity Read ↗

Intermittent treatment of BRAFV600E melanoma cells delays resistance by adaptive resensitization to drug rechallenge.Semantic proximity Read ↗

Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.